Biospectrum India, a leading print publication for the biopharma industry, had a special issue on Generative AI in Oct 2023. The cover story carried the views of Molecule AI Director, Neeta Singal.

MoleculeAI
2 min readOct 4, 2023

Neeta Singal, Director, Molecule AI, opines that India’s strong foundation in IT and software development positions it favourably to excel in AI solutions for life sciences and healthcare — spanning drug discovery, medical imaging analysis, disease prediction, and personalised treatments.

Also, according to Neeta Singal, leveraging its vast and diverse population, India can harness abundant data to train AI models tailored to its populace. “In applications like drug discovery, AI’s appeal lies in expediting drug development by streamlining certain processes. The integration of Generative AI might reduce the need for extensive wet lab testing, impacting business and employment at contract research organisations (CROs). Similarly, AI’s potential to produce more drug candidates could render some roles redundant for medicinal chemists at major pharmaceutical companies. This trend extends to in vivo tests as well. While AI’s enhanced productivity and economic efficiency might foster job growth overall, it is plausible that certain positions will be displaced,” says Neeta.

--

--

MoleculeAI

This page would let you know about the interesting developments in the field of Drug discovery to cure neurogenerative diseases, using artificial intelligence.